Haleon UK Capital Plc, founded in 2022 and headquartered in the United Kingdom, is a leading consumer health company committed to delivering health-focused products. As a spin-off from GlaxoSmithKline, Haleon specializes in wellness, oral health, pain relief, respiratory health, and dietary supplements, catering to the needs of consumers globally.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| HALEON 2.88% 2028-09-18 EURHaleon UK Capital Plc | United Kingdom | 2028-09-18 | 2.875 | 2.57 |
| HALEON 2.88% 2028-10-29 GBPHaleon UK Capital Plc | United Kingdom | 2028-10-29 | 2.875 | 4.26 |
| HALEON 3.13% 2025-03-24 USDHaleon UK Capital Plc | United Kingdom | 2025-03-24 | 3.125 | 0.00 |
| HALEON 3.13% 2025-03-24 USDHaleon UK Capital Plc | United Kingdom | 2025-03-24 | 3.125 | 0.00 |
| HALEON 3.13% 2025-03-24 USDHaleon UK Capital Plc | United Kingdom | 2025-03-24 | 3.125 | 0.00 |
| HALEON 4.63% 2033-09-18 GBPHaleon UK Capital Plc | United Kingdom | 2033-09-18 | 4.625 | 5.20 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Haleon UK Capital Plc began its bond issuance shortly after its establishment as an independent entity, with its first notable issuance occurring in mid-2022 to support operational and strategic initiatives. The company has since attracted significant interest from investors, evidenced by its successful €1 billion bond offering in late 2022, which featured a 5-year maturity and a yield that is competitive within the industry, reflecting strong demand for consumer health securities. Recent developments in the bond market indicate that Haleon’s debt instruments are enhancing the firm’s liquidity, with plans for future issuances expected to further bolster its financial position amidst a growing health-conscious consumer base.